Actively Recruiting
Evaluating Omission of Postoperative Radiotherapy in Women Aged 40 and Older with Low- to Intermediate-Risk ER-Positive DCIS After Breast-Conserving Surgery
Led by Fudan University · Updated on 2026-08-13
636
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase III randomized trial to assess if skipping postoperative radiotherapy is acceptable for women aged 40 and older with low- or intermediate-risk ductal carcinoma in situ DCIS that is estrogen receptor-positive and HER2-negative. This study focuses on patients who have undergone breast-conserving surgery with specific tumor characteristics such as size no larger than 2.5 cm, negative surgical margins of at least 3 mm, no comedo necrosis, and unifocal disease detected by screening. The trial aims to compare outcomes between receiving radiotherapy after surgery versus observation alone in this patient group. Participants will be randomly assigned to one of two groups one receiving adjuvant radiotherapy after surgery alongside endocrine therapy with tamoxifen, and the other undergoing observation after surgery with standard follow-up and tamoxifen therapy. The radiotherapy options include partial breast irradiation or whole breast hypofractionated regimens, delivered within three months post-surgery. The study is designed to evaluate whether omitting radiotherapy maintains acceptable tumor recurrence rates. During the trial, participants will be monitored over five years to measure outcomes such as ipsilateral breast tumor recurrence, local-regional recurrence, survival metrics, and treatment-related toxicities. Quality of life will also be assessed through validated questionnaires. Follow-up includes regular clinical assessments and pathology review. The total participation duration spans up to ten years, covering primary outcome evaluation and extended safety monitoring.
CONDITIONS
Brief Title
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery
Research Team
X
Xiaoli Yu
J
Jin Meng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here